The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11).
Irinotecan (CPT-11) is an anticancer drug that occasionally produces acute cholinergic side effects. Preliminary findings suggest that these are mediated through the inhibition of acetylcholinesterase (AChE). In this study, the inhibition of various AChEs by CPT-11 was studied. The lactone form of CPT-11 resulted in apparent noncompetitive inhibition of electric eel and both human recombinant and erythrocyte AChE with K(i) values of 0.065, 0.19, and 0.29 microM, respectively. The carboxylate form of CPT-11 was approximately 10 times less potent. Apparent noncompetitive inhibition of AChE may arise through several mechanisms, and those relevant to CPT-11 were identified from key experimental findings. First, the inhibition by CPT-11 was found to be instantly reversible in dilution studies. Second, incubation of the enzyme with CPT-11 before the introduction of neostigmine protected the enzyme from inactivation. Third, regeneration of the active enzyme after preincubation with neostigmine was totally suppressed by the addition of 2 microM CPT-11, indicating that CPT-11 is a potent inhibitor of decarbamoylation and, by inference, deacylation. Additional experiments with tacrine revealed functional differences between these two inhibitors. Also, preliminary molecular modeling of the interaction between AChE and CPT-11 indicated that the latter does not bind at the same site as tacrine. Displacement studies with the peripheral site-specific ligand, propidium, confirmed that CPT-11 binds at this site. The rapid reversibility of the inhibition of AChE by CPT-11 and the lower activity of the carboxylate form are likely reasons for the transient nature of the cholinergic toxicity observed clinically.
Dodds
H M
HM
Department of Medicine, University of Queensland, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Rivory
L P
LP
D000110:Acetylcholinesterase / Q000187:drug effects / Q000378:metabolism*; D000215:Acylation / Q000187:drug effects; D000544:Alzheimer Disease / Q000188:drug therapy; D001667:Binding, Competitive; D002091:Butyrylcholinesterase / Q000187:drug effects / Q000378:metabolism; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004912:Erythrocytes / Q000201:enzymology; D006801:Humans; D006868:Hydrolysis; D000077146:Irinotecan; D007700:Kinetics; D009388:Neostigmine / Q000494:pharmacology; D011419:Propidium / Q000494:pharmacology; D013379:Substrate Specificity; D013619:Tacrine / Q000494:pharmacology
D002800:Cholinesterase Inhibitors; D011419:Propidium; D009388:Neostigmine; D013619:Tacrine; D000077146:Irinotecan; D000110:Acetylcholinesterase; D002091:Butyrylcholinesterase; D002166:Camptothecin